GAGiancarlo Alvarado-Gamarra

Giancarlo Alvarado-Gamarra

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article


Giancarlo Alvarado-Gamarra has a total of 154 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Open Access

    Enfermedad de Castleman unicéntrica mortal con pénfigo paraneoplásico y bronquiolitis obliterante en paciente pediátrico: reporte de caso

    by Danny Asparrin Ramos, Giancarlo Alvarado Gamarra, Matilde Estupiñan Vigil, Raquel Garcés Ghilardi, Miriam Salas Olortegui, Lissett Castillo Vasquez

    Introducción. La enfermedad de Castleman (EC) es una neoplasia linfoproliferativa infrecuente que puede asociarse con el pénfigo paraneoplásico (PPN) y, en casos excepcionales, con bronquiolitis obliterante (BO). Reporte del caso. Niña de 12 años con pérdida de peso y lesiones ulceradas orales, diagnosticada con PPN. La tomografía torácica evidenció una masa mediastinal resecada completamente, cuyo estudio histológico confirmó una EC unicéntrica hialino-vascular. Tres meses después de la cirugía desarrolló disnea, tos y sibilancias persistentes, sin respuesta a tratamiento con corticosteroides, metotrexato, azitromicina, montelukast y tocilizumab. La paciente evolucionó a insuficiencia respiratoria crónica y falleció diez meses después del diagnóstico inicial. Conclusión. Este caso ilustra una evolución inusual y fatal de EC unicéntrica asociada a PPN y BO, subrayando la importancia del reconocimiento precoz y el seguimiento multidisciplinario ante posibles complicaciones autoinmunes incluso tras la resección tumoral completa.

  • Open Access

    Clinical Characteristics, Management, and Prognosis of Newborns with Aplasia Cutis Congenita Type I: A Systematic Review and Case Report

    by Leonardo J. Uribe-Cavero, Fabián A. Chavez-Ecos, Marisella Chumán-Sánchez, Alexander M. Parra-Huaroto, Jesús Neyra-Leon, Dayana O. Torres-Huamani, Anthony Siguas-Huasquiche, Solange Tarazona-Vilca, Elías E. Bohorquez-Espino, Maribel Anchante-Centeno, et al.

    Objectives: To synthesize the clinical characteristics, management, and outcomes of newborns with aplasia cutis congenita (ACC) type I. Introduction: ACC type I is a rare congenital condition characterized by isolated scalp defects without associated malformations. Evidence is limited and fragmented. Methods: We conducted a systematic review of studies reporting individual-level clinical data, including case reports, case series, and correspondence describing individual patients, following PRISMA guidelines. An additional clinical case was included. Results: Thirty-six studies, including 69 newborns, were analyzed. Most lesions were solitary (84.1%), located on the vertex (61.9%), superficial (55%), and more frequent in males (60.9%). Management was predominantly surgical. Complications were uncommon (21.3%), and outcomes were generally favorable. Conclusion: ACC type I typically presents as an isolated scalp defect with a favorable prognosis. Lesion characteristics and risk of complications should guide management.

  • Post-MIS-C cardiovascular outcomes: a systematic review

    by Giancarlo Alvarado-Gamarra, Katherine Alcala-Marcos, Carlos R. Celis, Pía Balmaceda-Nieto, Luigi Cieza, Cristian Morán-Mariños, Pamela Grados-Espinoza, Carlos Alva-Díaz, Lucie Ecker, Theresa J. Ochoa, et al.

    Limited knowledge and variability in findings exist regarding the resolution of cardiovascular outcomes following Multisystem Inflammatory Syndrome in Children (MIS-C). We conducted a systematic review to estimate the frequency of cardiovascular outcomes following MIS-C. A systematic search was conducted in Pubmed/Medline, Scopus, Embase, SciELO, LILACS, Cochrane Library, Web of Science, and medRxiv were searched up to February 2024. We included studies reporting cardiovascular events that began in acute MIS-C and persisted after discharge. Screening and data extraction were performed by independent reviewers. We performed a random-effects meta-analysis and assessed the certainty of the evidence using the GRADE approach. Eighty-four studies (n = 4,778) were included; seven had a comparator group. The frequency of cardiovascular outcomes—including coronary abnormalities (Z-score ≥ 2), left ventricle ejection fraction < 55%, diastolic dysfunction, myocarditis, and pericardial effusion—decreased over time, with most resolving by 6 to 9 months. However, cardiac magnetic resonance imaging studies identified myocardial edema and/or fibrosis persisting up to 12 months, and two studies reported coronary abnormalities at 18- to 24-month follow-up. Evidence certainty was very low. Compared to children with COVID-19 or healthy controls, MIS-C showed more cardiovascular events and greater subclinical myocardial dysfunction, as assessed by strain analysis, during a 6-month follow-up. Compared with other etiologies of myocarditis, MIS-C myocarditis was associated with better cardiovascular outcomes but shorter exercise duration and lower aerobic capacity on stress testing. Conclusions: Cardiovascular outcomes following MIS-C improved over time, but certain subclinical cardiac abnormalities persisted up to 12 to 24 months. These findings may support long-term follow-up after MIS-C. Trial registration: Protocol registration number: PROSPERO, CRD42022336784. What is Known: • Multisystem Inflammatory Syndrome in Children (MIS-C) may lead to persistent cardiovascular complications. However, studies show variability in their findings, with heterogeneous follow-up durations—including limited long-term data—small sample sizes, and data mostly originating from single-center experiences in high-income countries. What is New: • Cardiovascular outcomes following MIS-C improved over time across global reports, most resolving by 6–9 months; however, advanced non-invasive methods have identified subclinical cardiac abnormalities up to 12–24 months. This may support the development of evidence-based follow-up recommendations after MIS-C.


  • Open Access

    Clinical characteristics, treatments, and complications of Kawasaki disease in Peruvian children: a retrospective observational study

    by Noé Atamari-Anahui, Giancarlo Alvarado-Gamarra, Nadin Conto-Palomino, Stephanie Cabello-Coca, Jessica La Torre Torreblanca, Danny Asparrin Ramos, María Fernanda Rosado Rullier, Olguita del Aguila, Jorge Candela-Herrera

    Background: Kawasaki disease (KD) is a rare medium-sized vessel vasculitis that is the leading cause of acquired heart disease in children. However, most studies on KD focused on its occurrence in infants aged <6 months. Objectives: To evaluate the clinical characteristics, treatments, and complications of KD in Peruvian children. Design: Retrospective observational study. Methods: We collected data from patients aged <18 years who were diagnosed with KD and hospitalized at four healthcare institutions in Lima, Peru, between 2010 and 2022. Clinical characteristics, treatments, and complications were described overall and by age (groups A: <6 months, B: 6 to <12 months, C: 1 to 10 days. A second dose of immunoglobulin was administered to 32 patients, and corticosteroids were administered to 48 patients (21.3%). Immunoglobulin resistance occurred in 14.8% of the patients, predominantly in group D. Coronary aneurysms were observed in 25 patients (12.1%), predominantly in group A. Two patients required intensive care unit admission, and no deaths occurred during hospitalization. Conclusion: Mucocutaneous manifestations of KD in Peruvian children are consistent with those reported in other populations. The frequency of aneurysms and immunoglobulin resistance differed according to age. We emphasize the importance of understanding the clinical presentation of KD, both overall and stratified by age, to prevent late diagnosis and ensure timely treatment.

  • Open Access

    Hemophagocytic lymphohistiocytosis as the initial manifestation of bone marrow failure in a child with a TERC variant telomere biology disorder

    by Daniel Medina-Neira, Giancarlo Alvarado-Gamarra, Brenda Huamaní-Condori, Nelson Purizaca-Rosillo, Noé Atamari-Anahui, Erick Matos-Villena, Raquel Garces-Ghilardi, Matilde Estupiñan-Vigil

    Hemophagocytic lymphohistiocytosis (HLH) is a life-threatening systemic hyperinflammatory syndrome, rarely associated with bone marrow failure (BMF). Telomere biology disorders (TBD) are caused by inherited defects in telomerase processes and can have heterogeneous presentations including idiopathic pulmonary fibrosis, cirrhosis, and BMF. We report a case of a 10-year-old male from Lima, Peru, who presented with HLH as the initial manifestation of a TBD. He experienced fever, gastrointestinal symptoms, and mucocutaneous involvement. Initial laboratory analyses revealed pancytopenia and elevated inflammatory markers. Despite symptomatic and antibiotic treatment, his clinical condition persisted leading to a suspicion of Kawasaki disease and, subsequently, HLH. Immunomodulatory treatment was initiated with a good clinical response. Bone marrow aspiration revealed severe hypocellular bone marrow and cytophagocytosis. Genetic studies identified a pathogenic variant in the TERC gene (n.110_113del), which was also found in the patient’s mother and brother. HLH as the initial manifestation of BMF is rare. This case highlights the importance of considering TBD in children with BMF of unclear etiology and the value of genetic testing in such cases.


  • Open Access

    Poliartritis como debut de leucemia linfoblástica aguda

    by Danny Asparrin Ramos, Roxana Díaz Subauste, Giancarlo Alvarado­-Gamarra, Raquel Garcés Ghilardi, Matilde Estupiñan Vigil, Lissett Castillo Vasquez

    Objetivo: Reportar un caso de leucemia linfoblástica aguda (LLA) en un niño con diagnóstico inicial de poliartritis. Material y métodos: Revisión de historia clínica y diversos estudios diagnósticos, incluyendo ecografía articular, survey óseo, gammagrafía, tomografía y aspirado de médula ósea. Reporte del caso: Niño de 4 años de Iquitos, Perú, con poliartritis migratoria, dolor articular, tumefacción, limitación funcional y fiebre intermitente, con persistencia de los síntomas. Se identifican lesiones líticas en huesos de la mano y radio derecho, adenopatía axilar derecha, hepatomegalia, anemia, leucopenia y trombocitosis. Tras tratamiento antibiótico sin respuesta, se confirma LLA tipo B por aspirado de médula ósea. Recibe quimioterapia, logrando la remisión de los síntomas articulares. Conclusión: Las manifestaciones articulares como debut de LLA, especialmente sin blastos en sangre periférica, representan un reto diagnóstico. Es crucial mantener una alta sospecha para un diagnóstico y tratamiento oportunos, mejorando la supervivencia del paciente.

  • Open Access

    Artritis idiopática juvenil de inicio sistémico como síndrome paraneoplásico de un astrocitoma difuso

    by Danny Asparrin Ramos, Roxana Díaz Subauste, Giancarlo Alvarado-­gAmarra, Raquel Garcés Ghilardi, Matilde Estupiñan Vigil, Miriam Salas Olórtegui

    Objetivo: Se reporta el caso de una niña de 8 años con artritis idiopática juvenil (AIJ) de inicio sistémico como síndrome paraneoplásico de un astrocitoma difuso. Materiales y métodos: Revisión de historia clínica, paraclínicos, ecografía, resonancia magnética cerebral, biopsia cerebral e inmunohistoquímica. Reporte del caso: El paciente presentó síntomas de AIJ durante 2 años, con adenopatías, fiebre, astenia y oligoartralgias, que no respondieron al tratamiento convencional. Tres meses antes del ingreso, desarrolló asimetría facial y hemiparesia derecha. La resonancia magnética reveló una lesión cerebral de 6x4 cm que afectaba varias estructuras. Se realizó resección parcial de tumor, diagnosticándose astrocitoma difuso grado II. Posteriormente, el paciente recibió quimioterapia, logrando la remisión de las artralgias y mejoría en la hemiparesia. Conclusión: Este es el primer caso reportado de AIJ asociado con astrocitoma difuso. Se subraya la importancia de excluir otras enfermedades en el diagnóstico de AIJ para segurar un tratamiento oportuno.

  • Open Access

    Edad como predictor de la severidad de la COVID-19 en pacientes pediátricos: una cohorte retrospectiva en un hospital de referencia del Perú

    by Sara Chávez-Alvarado, Miguel Quispe-Chipana, Giancarlo Alvarado-Gamarra, Daniel Enríquez-Vera, Lesly Chávez-Rimache, Matilde Estupiñan-Vigil, Anthony Romero-Cerdán, Alvaro Quincho-Lopez, Jimena Saavedra-Diaz, Iris Vargas-Chávez, et al.

    Objective: To estimate the role of age as a predictor of COVID-19 severity in pediatric patients hospitalized with a COVID-19 diagnosis at a reference hospital in Peru. Materials and methods: A retrospective cohort study was conducted, including pediatric patients from one month old to less than 14 years of age, hospitalized between May 2020 and December 31, 2021, at the Edgardo Rebagliati-Martins National Hospital. The exposure variable was age, categorized in six-month intervals. The outcome variable was the severity of COVID-19, determined according to the severity criteria established in the EsSalud Clinical Practice Guidelines for the management of COVID-19 in pediatrics. Crude and adjusted relative risks (RR) were estimated, with their respective 95% confidence intervals (95% CI). Results: Three-hundred and thirty-one patients were analyzed, their median age was 94 months (7,8 years), and the male-to-female ratio was 1.23. Comorbidities were present in 59.5% of the patients, with neurological disorders being the most common (13.9%). Fatalities were 3.3% of the whole sample, and 63.6% of them were severe cases. Severe COVID-19 was found in 9.4% of the sample. In the adjusted regression model, increasing age was not found to be a predictor of reduced risk of COVID-19 severity (adjusted RR= 1.02; 95% CI 0.98-1.06). Conclusion: Our study did not find age as a predictor of COVID-19 severity in hospitalized pediatric patients. Future studies are recommended to further explore and contrast our findings.

  • Open Access

    A comparative analysis of heme vs non-heme iron administration: a systematic review and meta-analysis of randomized controlled trials

    by Mariano Gallo Ruelas, Giancarlo Alvarado-Gamarra, Adolfo Aramburu, Gandy Dolores-Maldonado, Karen Cueva, Gabriela Rojas-Limache, Carmen del Pilar Diaz-Parra, Claudio F. Lanata

    Background and purpose Bioavailability studies and observational evidence suggest that heme iron (HI) may have greater impact on iron status indicators compared with non-heme iron (NHI). This systematic review and meta-analysis aimed to review the current evidence on the effect of the administration of HI compared with NHI for improving iron status in non-hospitalized population groups. Methods We searched Pubmed, CENTRAL, Scopus, Web of Science, and LILACS from inception to July 2024. There was no language restriction or exclusion based on age or iron status. Only randomized controlled trials comparing HI with NHI were considered. A random-effects meta-analysis was performed to compare the effect of treatments for iron status indicators and total side effects (including gastrointestinal side effects). We measured the certainty of the evidence (CoE) using GRADE assessment. Results After screening 3097 articles, 13 studies were included. Most of the interventions used HI in low doses combined with NHI. The meta-analysis showed higher hemoglobin increases in children with anemia or low iron stores receiving HI (MD 1.06 g/dL; 95% CI: 0.34; 1.78; CoE: very low). No statistically significant difference between interventions were found for any iron status indicator in the other population subgroups (CoE: very low). Participants receiving HI had a 38% relative risk reduction of total side effects compared to NHI (RR 0.62; 95% CI 0.40; 0.96; CoE: very low). Conclusion The current evidence comparing HI with NHI is very limited, preliminary findings suggest that interventions using HI may result in fewer side effects and may be superior in children with iron deficiency or anemia. However, given the very low certainty of the evidence, these results need further investigation through high-quality clinical trials. Protocol registration CRD42023483157.


  • Open Access

    A comparative analysis of heme vs non-heme iron administration: a systematic review and meta-analysis of randomized controlled trials

    by Mariano Gallo Ruelas, Giancarlo Alvarado-Gamarra, Adolfo Aramburu, Gandy Dolores-Maldonado, Karen Cueva Rodríguez, Gabriela Rojas-Limache, Carmen del Pilar Diaz-Parra, Claudio F. Lanata

    Background and purpose: Bioavailability studies and observational evidence suggest that heme iron (HI) may have greater impact on iron status indicators compared with non-heme iron (NHI). This systematic review and meta-analysis aimed to review the current evidence on the effect of the administration of HI compared with NHI for improving iron status in non-hospitalized population groups. Methods: We searched Pubmed, CENTRAL, Scopus, Web of Science, and LILACS from inception to July 2024. There was no language restriction or exclusion based on age or iron status. Only randomized controlled trials comparing HI with NHI were considered. A random-effects meta-analysis was performed to compare the effect of treatments for iron status indicators and total side effects (including gastrointestinal side effects). We measured the certainty of the evidence (CoE) using GRADE assessment. Results: After screening 3097 articles, 13 studies were included. Most of the interventions used HI in low doses combined with NHI. The meta-analysis showed higher hemoglobin increases in children with anemia or low iron stores receiving HI (MD 1.06 g/dL; 95% CI: 0.34; 1.78; CoE: Very low). No statistically significant difference between interventions were found for any iron status indicator in the other population subgroups(CoE: Very low). Participants receiving HI had a 38% relative risk reduction of total side effects compared to NHI (RR 0.62; 95% CI 0.40; 0.96; CoE: Very low). Conclusion: The current evidence comparing HI with NHI is very limited, preliminary findings suggest that interventions using HI may result in fewer side effects and may be superior in children with iron deficiency. However, given the very low certainty of the evidence, these results need further investigation through high-quality clinical trials.